Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00315549 · ClinicalTrials.gov registry record · Phase 3

TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults

A Phase 3 study, sponsored by Sanofi.

Terminated
Registry status
Phase 3
Development phase
233
Enrollment target

NCT00315549: Clinical Trial Phase 3 study, sponsored by Sanofi.

NCT00315549 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 233 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00315549, a Phase 3 study, was terminated before completion, sponsored by Sanofi.

TERMINATED
Registry status
Phase 3
Development phase
233 participants
Enrollment target

Study Summary

This is a multinational, randomized (1:1), double blind, comparator-controlled, 2 parallel treatment group study in subjects equal to or over 13 years of age, with Streptococcus pyogenes tonsillitis/pharyngitis (T/P). Each subject will receive either telithromycin, 400 mg over-encapsulated tablets, 800 mg once daily for 5 days or penicillin V 250 mg over-encapsulated tablets, 500 mg three times daily for 10days. Matching placebo capsules will be dispensed to maintain the blind between the treatment groups.A positive rapid identification test for streptococcal Group A antigen will be required for all subjects at Visit 1 (Day 1) for entry into the study. Throat swab specimens for bacterial culture, identification, and antibiotic-susceptibility testing will be taken at Visits 1, 3 and 4.

Interventions

  • DRUG Penicillin
  • DRUG Telithromycin

Trial Details

FieldValue
Enrollment Target 233 participants
Start Date 2006-02
Est. Completion 2006-09
Phase Phase 3
Sanofi

713 total trials

Why NCT00315549 stopped before completion

NCT00315549 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 2 interventions - of which Penicillin is the first listed.

NCT00315549 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00315549 about?

NCT00315549 is a clinical study titled "TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults". This is a multinational, randomized (1:1), double blind, comparator-controlled, 2 parallel treatment group study in subjects equal to or over 13 years of age, with Streptococcus pyogenes tonsillitis/pharyngitis (T/P). Each subject will receive either telithromycin, 400 mg over-encapsulated tablets, ...

What is the current status of trial NCT00315549?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 233 participants. The study started on 2006-02. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00315549?

The interventions under investigation include: Penicillin (DRUG), Telithromycin (DRUG).

Who is sponsoring clinical trial NCT00315549?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00315549's enrollment target sits among peer trials

233 1298th of 2000 higher than 703 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06993844 · 233 participants · Phase 1

    Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

  • NCT07141706 · 233 participants · Phase 1

    A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

  • NCT04942717 · 234 participants · NA

    Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

  • NCT05208671 · 234 participants · NA

    Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00315549, the US trial registry maintained by the National Library of Medicine. NCT00315549 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.